1. Subjects sign informed consent voluntarily.

2. Age 18-55 at screening (both included)，male or female（male only for part A）.

3. At screening, 20.0 kg/m2 ≤ BMI ≤ 24.9 kg/m2, body weight≥54.0 kg.

4. Female subjects were HCG negative at screening and baseline

1. Female subjects who are pregnant or lactating at screening.

2. History of drug abuse within 1 year prior to screening, with a positive drug abuse screening result at screening or before dosing.

3. Abnormal fasting blood glucose at screening, or impaired glucose tolerance, or history of hypoglycemia within 3 months prior to screening.

4. History of the following diseases with a definite diagnosis within 6 months prior to screening: cardiovascular disease, hematologic disease, respiratory disease, abnormal liver function due to acute and chronic hepatitis or other reasons, abnormal renal function, endocrine and metabolic system disease, neuropsychiatric disease, skin and subcutaneous tissue disease, musculoskeletal system disease, immune system disease, or the presence of other diseases that may interfere with the interpretation of study results.

5. Those who have any food allergies or special dietary requirements and cannot follow a uniform diet.